It wouldn’t be wise to expect anything big in a hurry, but it is now clear that the Sanpower Group, which acquired Dendreon about a year ago, has serious plans to do things that the “old Dendreon” never did to optimize the potential of sipuleucel-T (Provenge). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: access, availability, Provenge, sipuleucel-T | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 